Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 456.79% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the stock. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Benchmark reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. TD Cowen reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $13.00.

Humacyte Stock Performance

Shares of HUMA stock opened at $4.49 on Thursday. The business has a 50 day simple moving average of $5.31 and a 200 day simple moving average of $6.19. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The firm has a market capitalization of $565.11 million, a price-to-earnings ratio of -3.35 and a beta of 1.47. Humacyte has a 12-month low of $2.43 and a 12-month high of $9.97.

Insider Activity

In other news, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the transaction, the chief executive officer now owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. The trade was a 6.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. This represents a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,584,153 shares of company stock worth $13,476,796 over the last 90 days. 11.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. nVerses Capital LLC purchased a new position in Humacyte in the second quarter valued at about $28,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte in the 3rd quarter valued at approximately $75,000. Principal Financial Group Inc. acquired a new position in Humacyte in the second quarter worth approximately $83,000. FORA Capital LLC bought a new position in Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new stake in Humacyte in the second quarter valued at approximately $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.